In discussion with… Alcentra’s Peter Glaser
What makes a direct lending fund manager tick? Alcentra fund manager Peter Glaser provides a behind-the-scenes overview of this sometimes-overlooked asset class.
What makes a direct lending fund manager tick? Alcentra fund manager Peter Glaser provides a behind-the-scenes overview of this sometimes-overlooked asset class.
Paul Benson discusses his route to a career in fund manager and why he believes there is opportunity in fallen angels
Can the ‘complexity premium’ of structured credit offer investors uncorrelated returns? Read this Q&A with Alcentra fund manager Hiram Hamilton to find out.
Newton fund manager Ian Smith explains what brought him to investing and why emerging markets matter.
How can a multi-asset approach aid fixed income investors? Read our Q&A with Insight Investments fund manager Steve Waddington to find out
Newton’s Ilga Haubelt asks: Which income stocks held their own in 2020 and which are best placed to shine in the coming year?
State and local governments could see renewed strength this year, says Mellon strategist Sherri Tilley.
Mellon’s David LeDuc explains why stability could be they key to recovery in 2021.
Income investors faced a challenge in 2020. Will things come good in 2021?
As the UK reinvents itself as an independent sovereign state – but with an EU trade agreement in place – just what will this mean for business, investment and the wider UK and European economies? Here BNY Mellon Investment Management firms share their thoughts
In a world of growing social and governance awareness it is vital investors understand and manage their exposure to supply chain risks, says Newton head of responsible investment, Ian Burger.
The next era of cloud computing has meaningful implications not just for business but geopolitics and the environment. Walter Scott explains why.
The prospects of rising inflation and the growing application of Environmental, Social and Governance (ESG) factors in fixed income are likely to be key considerations for bond investors in the year ahead, says Newton head of fixed income Paul Brain.
The science behind genetic therapies is a rapidly developing field of biotechnology. But can it be harnessed for investing?
In our second annual sentiment survey we asked our fund managers and analysts for their views on the year ahead. Read on to learn their views on what 2021 may bring.
